Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 11/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21375648 | 0.84 | SIGMAR1 (0.60) | OPRM1CHRM2CHRM3SIGMAR1 | |
| SCHEMBL4260839 | 0.82 | GAA (0.60) | OPRM1OPRD1OPRK1GAACHRM2 | |
| SCHEMBL3041150 | 0.81 | LTA4H (0.68) | OPRD1CHRM2CHRM3CHRM4 | |
| SCHEMBL6156880 | 0.80 | CHRM2 (0.54) | OPRM1OPRD1OPRK1CHRM2CHRM3 | |
| SCHEMBL27473621 | 0.79 | SIGMAR1 (0.65) | OPRM1CHRM2CHRM3SIGMAR1 | |
| SCHEMBL6070072 | 0.78 | GAA (0.70) | OPRM1OPRD1OPRK1GAACHRM4 | |
| SCHEMBL6154064 | 0.78 | GAA (0.70) | OPRK1GAA | |
| SCHEMBL1869809 | 0.78 | CHRM2 (0.64) | CHRM2CHRM3SIGMAR1 | |
| SCHEMBL8230948 | 0.77 | HDAC1 (0.54) | OPRM1OPRD1OPRK1GAACHRM4 | |
| SCHEMBL6153849 | 0.77 | GAA (1.00) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | OPRM1 1474/4885OPRD1 1102/4885OPRK1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.